Welcome!

News Feed Item

Yew Bio-Pharm Group Reports 2013 Fourth Quarter And Full Year Financial Results

HARBIN, China, March 31, 2014 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today reported financial results for the three- and twelve-months ended December 31, 2013.

2013 Fourth Quarter Results           


Three Months Ended December 31,

Twelve Months Ended December 31,


2013

2012

2013

2012

Revenues:





TCM Raw Materials

$998,934

$884,796

$4,170,748

$3,745,348

Yew Trees

909,311

966,464

3,011,728

2,819,968

Handicrafts

81,770

43,474

257,172

162,208

Total Revenues

$1,990,015

$1,894,734

$7,439,648

$6,727,524

Total revenue for the fourth quarter of 2013 increased 5.0% to $2.0 million from $1.9 million a year ago.  Sales of TCM raw materials amounted to 50.2% of total revenues, sales of yew trees amounted to 45.7% of total revenues, and sales of handicrafts made up the remaining 4.1%. 

For the 2013 fourth quarter gross profit was $1.3 million, or 65.6 % of total revenue, compared with $1.5 million, or 76.7% of total revenues for the comparable 2012 quarter. Gross profit was primarily impacted by the remanufacturing of yew trees into TCM from whole plants at the Qingshan plant.

Operating expenses were $262,982 in the quarter, as compared to $2.6 million in the year-ago quarter, which included stock-based compensation of $2.5 million.

Net income in the fourth quarter of 2013 was $1.0 million, or $0.02 per diluted share, compared with a net loss of $1.2 million in the year-ago quarter, or $0.02 per share.

2013 Results

Total revenues for the 2013 fiscal year were $7.4 million, a 10.6% increase from $6.7 million a year earlier.  Sales of TCM raw materials amounted to 56.1% of total revenues, sales of yew trees amounted to 40.5% of total revenues, and sales of handicrafts made up the remaining 3.4%.

Gross profit was $5.0 million, or 67.6% of total revenues, for the full year, compared with $5.4 million, or 81.0% of total revenues in 2012. 

Operating expenses were $1.1 million for the year ended December 31, 2013, compared with $3.2 million a year earlier.

Net income for 2013 increased to $3.9 million, or 0.08 per diluted share, from $2.2 million, or $0.05 per diluted share for 2012.

"During fiscal 2013, we were able to achieve growth across all revenue categories, selling more than 24,000 kg of TCM raw materials and nearly 500,000 yew trees," said Mr. Zhiguo Wang, Chairman and Chief Executive Officer of Yew Bio-Pharm Group. "To increase our growth trajectory, we are expanding our sales and marketing efforts to new customers, as well as continuing to evaluate land leasing opportunities.

"Through our patented Asexual Reproduction Method, we are able to significantly shorten the maturity cycle of naturally-grown yew trees, in as little as three years compared to more than 50 years for naturally grown yew trees. This allows for earlier commercialization while not further endangering the China's natural supply of yew trees, which were over-forested since the discovery of taxol," Mr. Wang added.  

ABOUT YEW BIO-PHARM GROUP, INC

Yew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers.  The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them. To learn more, please visit www.yewchina.com

SAFE HARBOR

This press release forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.  These forward-looking statements involve a number of risks and uncertainties that could cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.  A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: our ability to collect from our largest customers; our dependence on a small number of customers for raw materials, including a related party; our ability to continue to purchase raw materials at relatively stable prices; our dependence on a small number of customers for our yew trees for reforestation; our ability to market successfully raw materials used in the manufacture of traditional Chinese medicines; and our ability to receive continued preferential tax treatment for the sale of yew trees and potted yew trees.  From time to time, these risks, uncertainties and other factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form 10-K.  Yew Bio does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise, except as required under applicable law.

Company Contacts:

Henry Pang

Yew Bio-Pharm Group, Inc.

Tel: (702) 487-4683

[email protected]

Investor Relations Contacts:

Judy Lin Sfetcu / Matt Sheldon

PondelWilkinson Inc.

Tel: 310-279-5980

[email protected]

(financial tables follow)

YEW BIO-PHARM GROUP, INC. AND SUBSIDIARIES 

CONSOLIDATED BALANCE SHEETS









 December 31, 


2013


2012







ASSETS






CURRENT ASSETS:






    Cash

$

1,159,611


$

386,821

    Accounts receivable


418,875



722,598

    Accounts receivable - related party


377,821



284,986

    Inventories


1,089,087



991,234

    Prepaid expenses and other assets


2,697



150

    Prepaid expenses - related party


34,031



60,245







        Total Current Assets


3,082,122



2,446,034







LONG-TERM ASSETS:






    Inventories, net of current portion


10,245,146



9,382,164

    Property and equipment, net


1,033,078



885,969

    Land use rights and yew forest assets, net


20,953,562



15,328,318







        Total Long-term Assets


32,231,786



25,596,451







        Total Assets

$

35,313,908


$

28,042,485







LIABILITIES AND SHAREHOLDERS' EQUITY






CURRENT LIABILITIES:






    Accounts payable

$

-


$

990

    Accrued expenses and other payables


136,713



199,098

    Taxes payable 


10,232



5,722

    Due to related parties


4,850,637



47,876







        Total Current Liabilities


4,997,582



253,686







        Total Liabilities


4,997,582



253,686







COMMITMENTS AND CONTINGENCIES












SHAREHOLDERS' EQUITY:






    Common Stock ($0.001 par value;  50,000,000 shares authorized;  50,000,000  and 






     50,000,000 issued and outstanding at December 31, 2013 and 2012, respectively)


50,000



50,000

    Additional paid-in capital


8,058,165



10,396,377

    Retained earnings


16,664,138



13,182,032

    Statutory reserves


2,597,118



2,179,494

    Accumulated other comprehensive income - foreign currency translation adjustment


2,946,905



1,980,896







        Total Shareholders' Equity


30,316,326



27,788,799







        Total Liabilities and Shareholders' Equity

$

35,313,908


$

28,042,485







 

YEW BIO-PHARM GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME














Three-Months Ended


Twelve-Months Ended


December 31, 


December 31, 


2013


2012


2013


2012

REVENUES:












    Revenues

$

1,848,698


$

1,482,606


$

5,889,190


$

5,713,237

    Revenues - related party


141,317



412,128



1,550,458



1,014,287













        Total Revenues


1,990,015



1,894,734



7,439,648



6,727,524













COST OF REVENUES:












    Cost of revenues


648,654



368,201



1,968,682



1,095,158

    Cost of revenues - related party


36,327



74,147



438,718



183,899













        Total Cost of Revenues


684,981



442,348



2,407,400



1,279,057













GROSS PROFIT


1,305,034



1,452,386



5,032,248



5,448,467













OPERATING EXPENSES:












     Selling


4,745



6,723



23,794



24,603

     Compensation


-



2,527,800



-



2,527,800

     Other general and administrative


258,237



71,776



1,110,717



691,562













        Total Operating Expenses


262,982



2,606,299



1,134,511



3,243,965













INCOME FROM OPERATIONS


1,042,052



(1,153,913)



3,897,737



2,204,502













OTHER INCOME (EXPENSES):












     Interest income


402



132



647



2,194

     Other income (expenses)


44



178



1,346



(429)













        Total Other Income (Expenses)


446



310



1,993



1,765













NET INCOME

$

1,042,498


$

(1,153,603)


$

3,899,730


$

2,206,267













COMPREHENSIVE INCOME:












      NET INCOME

$

1,042,498


$

(1,153,603)


$

3,899,730


$

2,206,267

      OTHER COMPREHENSIVE INCOME:












           Unrealized foreign currency translation gain


188,142



72,720



966,009



181,028













      COMPREHENSIVE INCOME

$

1,230,640


$

(1,080,883)


$

4,865,739


$

2,387,295













NET INCOME PER COMMON SHARE:












       Basic

$

0.02


$

(0.02)


$

0.08


$

0.05

       Diluted 

$

0.02


$

(0.02)


$

0.08


$

0.05













WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:










       Basic

50,000,000


47,819,672


50,000,000


47,819,672

       Diluted 

50,000,000


47,819,672


50,000,000


47,819,672

 

YEW BIO-PHARM GROUP, INC. AND SUBSIDIARIES 

CONSOLIDATED STATEMENTS OF CASH FLOWS























For the year ended 





December 31





2013


2012

CASH FLOWS FROM OPERATING ACTIVITIES:







Net  income

$

3,899,730


$

2,206,267


Adjustments to reconcile net income to net cash







         provided by operating activities:








         Depreciation



179,857



217,090


         Amortization of land use rights and yew forest assets



381,659



346,741


         Loss on disposal of fixed assets



349



1,013


         Stock-based compensation



-



2,246,907


Changes in operating assets and liabilities:







         Accounts receivable



323,160



(722,170)


         Accounts receivable - related party



(82,282)



(284,817)


         Prepaid and other current assets



(2,515)



284


         Prepaid expenses - related party



27,823



(60,209)


         Inventories



(222,738)



(2,090,046)


         Accounts payable



(1,008)



(1,369,280)


         Accrued expenses and other payables



(65,466)



78,597


         Due to related parties



-



(157,025)


         Taxes payable



4,255



5,211










NET CASH PROVIDED BY OPERATING ACTIVITIES


4,442,824



418,563










CASH FLOWS FROM INVESTING ACTIVITIES:







         Purchase of property and equipment



(299,613)



(313,908)


         Purchase of land use rights and yew forest assets



(3,393,082)



(392,136)










NET CASH USED IN INVESTING ACTIVITIES


(3,692,695)



(706,044)










CASH FLOWS FROM FINANCING ACTIVITIES:







         Repayments for related parties advances



(210)



(63,293)










NET CASH USED IN FINANCING ACTIVITIES


(210)



(63,293)










EFFECT OF EXCHANGE RATE ON CASH


22,871



5,224










NET DECREASE IN CASH


772,791



(345,550)










CASH  - Beginning of year


386,821



732,371










CASH - End of year

$

1,159,611


$

386,821










 

SOURCE Yew Bio-Pharm Group, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The dynamic nature of the cloud means that change is a constant when it comes to modern cloud-based infrastructure. Delivering modern applications to end users, therefore, is a constantly shifting challenge. Delivery automation helps IT Ops teams ensure that apps are providing an optimal end user experience over hybrid-cloud and multi-cloud environments, no matter what the current state of the infrastructure is. To employ a delivery automation strategy that reflects your business rules, making r...
Modern software design has fundamentally changed how we manage applications, causing many to turn to containers as the new virtual machine for resource management. As container adoption grows beyond stateless applications to stateful workloads, the need for persistent storage is foundational - something customers routinely cite as a top pain point. In his session at @DevOpsSummit at 21st Cloud Expo, Bill Borsari, Head of Systems Engineering at Datera, explored how organizations can reap the bene...
Kubernetes is an open source system for automating deployment, scaling, and management of containerized applications. Kubernetes was originally built by Google, leveraging years of experience with managing container workloads, and is now a Cloud Native Compute Foundation (CNCF) project. Kubernetes has been widely adopted by the community, supported on all major public and private cloud providers, and is gaining rapid adoption in enterprises. However, Kubernetes may seem intimidating and complex ...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
In his session at 21st Cloud Expo, Michael Burley, a Senior Business Development Executive in IT Services at NetApp, described how NetApp designed a three-year program of work to migrate 25PB of a major telco's enterprise data to a new STaaS platform, and then secured a long-term contract to manage and operate the platform. This significant program blended the best of NetApp’s solutions and services capabilities to enable this telco’s successful adoption of private cloud storage and launching ...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone in...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, discussed some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he covered some of the best practices for structured team migration an...
No hype cycles or predictions of a gazillion things here. IoT is here. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, an Associate Partner of Analytics, IoT & Cybersecurity at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He also discussed the evaluation of communication standards and IoT messaging protocols, data...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, discussed how given the magnitude of today's application ...